Topical Collection on Pathogenesis of Type 1 Diabetes

ISSN: 1534-4827 (Print) 1539-0829 (Online)

In this topical collection (31 articles)

previous disabled Page of 2
  1. No Access

    Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

    Interleukin-7 and Type 1 Diabetes

    Paolo Monti, Ezio Bonifacio Article:518
  2. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    Use of Metformin in Diseases of Aging

    John M. Miles, Andrew D. Rule, Barry A. Borlaug Article:490
  3. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    Cardiovascular Actions of GLP-1 and Incretin-Based Pharmacotherapy

    Angelo Avogaro, Saula Vigili de Kreutzenberg, Gian Paolo Fadini Article:483
  4. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes

    Morten Hansen, David P. Sonne, Filip K. Knop Article:482
  5. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    Systematic Reviews to Ascertain the Safety of Diabetes Medications

    Michael R. Gionfriddo, Oscar L. Morey-Vargas, Juan P. Brito Article:478
  6. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    Sulfonylureas: A New Look at Old Therapy

    Peter M. Thulé, Guillermo Umpierrez Article:473
  7. No Access

    Pharmacologic Treatment of Type 2 Diabetes (A Vella, Section Editor)

    The Potential of Cell-based Therapy for Diabetes and Diabetes-related Vascular Complications

    Aaron Liew, Timothy O’Brien Article:469
  8. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

    Magnus F. Grøndahl, Damien J. Keating, Tina Vilsbøll Article:128
  9. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    A Plethora of GLP-1 Agonists: Decisions About What to Use and When

    Susan L. Samson, Alan J. Garber Article:120
  10. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Pharmacological Management of Gestational Diabetes Mellitus

    Riki Bergel, Eran Hadar, Yoel Toledano, Moshe Hod Article:118
  11. Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus

    Gül Bahtiyar, David Gutterman, Harold Lebovitz Article:116
  12. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D

    Alan Sacerdote, Paulomi Dave, Vladimir Lokshin, Gül Bahtiyar Article:101
  13. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    SGLT2 Inhibitors: Benefit/Risk Balance

    André J. Scheen Article:92
  14. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

    Gül Bahtiyar, Jean Pujals-Kury, Alan Sacerdote Article:92
  15. No Access

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors)

    Hypoglycemia and Comorbidities in Type 2 Diabetes

    Alice P. S. Kong, Juliana C. N. Chan Article:80
previous disabled Page of 2